Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

174.80 +4.89 (+2.88%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

56 57 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug ↗

October 17, 2022

Via Benzinga

Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗

October 17, 2022

Via Benzinga

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

October 17, 2022

From Biogen Inc.

Via GlobeNewswire

Is This Stock a Buy After Soaring by 37%? ↗

October 06, 2022

Don't press the buy button too fast.

Via The Motley Fool

This Is What Whales Are Betting On Biogen ↗

October 13, 2022

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available...

Via Benzinga

Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗

October 13, 2022

Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.

Via Benzinga

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity ↗

October 13, 2022

Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.

Via Investor's Business Daily

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

October 13, 2022

From GoodRx

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13 ↗

October 13, 2022

Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.

Via Talk Markets

Is Seagen Stock a Buy Now? ↗

October 12, 2022

It's growing faster than competitors, but headwinds might soon bog it down.

Via The Motley Fool

Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗

October 12, 2022

Via Benzinga

Does Biogen's Recent Win Make It a Must-Buy Stock? ↗

October 12, 2022

Will Biogen investors be let down again, or is this the real deal?

Via The Motley Fool

4 Biotech Stocks With Huge Incoming Catalysts ↗

October 12, 2022

All four of these drugmakers are expecting important FDA approval decisions over the next few months.

Via The Motley Fool

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗

October 10, 2022

Via Benzinga

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

Eli Lilly Leads 5 Stocks To Watch In Bear Market ↗

October 08, 2022

Eli Lilly is holding up, while others crumbled Friday amid the market sell-off.

Via Investor's Business Daily

MarketBeat: Week in Review 10/3-10/7

October 08, 2022

The jobs report is fueling a sell-off to end the week with more volatility on tap for next week. Here are some of the most popular articles from this week.

Via MarketBeat

Topics Economy Electric Vehicles

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022 ↗

October 07, 2022

Upgrades

Via Benzinga

One Of Eli Lilly's Most Anticipated Drugs Could Hit The Market Next Year ↗

October 06, 2022

The Street is closely watching Lilly's efforts in obesity and Alzheimer's.

Via Investor's Business Daily

3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up

October 06, 2022

Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates

Via MarketBeat

Should You Sell Your FANGMAN Stocks? ↗

October 05, 2022

In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors.

Via Talk Markets

Hey Biogen Investors, Don’t Chase BIIB Stock! ↗

October 05, 2022

If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.

Via InvestorPlace

Will Investors Notice Exciting Sign On Biogen's Chart? ↗

October 05, 2022

If history is any guide, there may be good fortune ahead for shares of Biogen (NASDAQ:BIIB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

2 Signals to Watch Before Buying SAVA Stock ↗

October 05, 2022

SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.

Via InvestorPlace

Peering Into Biogen's Recent Short Interest ↗

October 04, 2022

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.61% of all regular shares that...

Via Benzinga

Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System ↗

October 04, 2022

Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB), Alector Inc.

Via Benzinga

Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ↗

October 03, 2022

Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.

Via Talk Markets

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.